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Abstract
Background: Therapy-refractory persistent hypoparathyroidism after extensive neck surgery is a rare but severe
complication. Parathyroid allotransplantation may represent a definitive treatment option.
Case presentation: A 32-year old female was referred to our hospital with intractable persistent hypocalcemia after
neck surgery for papillary thyroid cancer. Despite optimal medical treatment including calcium and vitamin D
supplementation and even hormonal replacement therapy hypocalcemic symptoms failed to improve. The quality of
life was considered very low. In light of the unsuccessful medical therapy and the young age of the patient parathyroid
allotransplantation seemed an attractive treatment option to restore normal calcium homeostasis despite of the need
for immunosuppressive therapy after the procedure. Therefore, we performed living-donor allotransplantation of two
healthy parathyroid glands to the recipient’s left forearm. The surgical intervention was successful. Neither the donor
nor the recipient showed any complications. In the postoperative course clinical symptoms of hypocalcemia
significantly improved whereas serum calcium and parathyroid hormone (PTH) levels progressively increased into
the normal range. Former intense replacement therapy could be discontinued completely in a stepwise fashion.
To date, nearly three years after transplantation, the patient remains asymptomatic with normal serum levels of
calcium and PTH.
Conclusion: Successful living-donor parathyroid allotransplantation for postsurgical hypoparathyroidism represents an
innovative therapeutic strategy that could provide the definitive treatment in those patients in which the disease is
therapy-refractory. The procedure can be justified even in nontransplant recipients. Retrieval of parathyroid glands from
healthy donors is feasible and safe.
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Background
Postsurgical hypoparathyroidism with symptomatic hypo-
calcemia after neck surgery is a common but usually tran-
sient complication. However, if hypocalcemia persists for
more than six months even with medical replacement
therapy and cryopreserved autologous parathyroid tissue
is not available, permanent hypoparathyroidism can lead
to dependence on high doses of calcium and vitamin D
supplementation [1–4]. Chronic hypocalcemia is signifi-
cantly associated with longterm risks of multiorgan calci-
nosis and renal failure. Symptoms related to hypocalcemia
can even be life-threatening (e.g. laryngeal spasm, refrac-
tory heart failure). Importantly, in rare cases hypocalcemia
cannot be controlled despite of aggressive oral supplemen-
tation of calcium and vitamin D and frequent additional
intravenous (i.v.) administration of calcium may be re-
quired seriously affecting the quality of life [5]. Recently,
novel synthetic PTH-replacement therapies have been ap-
proved showing promising results for patients who do not
respond well to treatment with calcium and active forms
of vitamin D alone. However, long-term hormonal treat-
ment may be limited because of the potential risk of bone
cancer [6, 7].
Allotransplantation of parathyroid cells could be an
ideal therapeutic option to establish physiologic treat-
ment for patients with persistent hypoparathyroidism.
Successful allotransplantation of parathyroid tissue from
deceased and living donors has been described sporadic-
ally in recent years. However, most of these procedures
were performed in kidney transplant recipients with on-
going immunosuppression [8–11].
We present - to the best of our knowledge – the first
successful case of living-related allotransplantation of
parathyroid glands obtained from a healthy donor in a
nontransplant patient suffering from therapy-refractory
postsurgical hypoparathyroidism.
Case presentation
Our patient is a 32-year old white female patient who
underwent surgery for multinodular goiter in 2006. Dur-
ing surgery, a papillary thyroid carcinoma had been
detected (final histology: pT2, pN0, R0). Therefore, ex-
tensive neck dissection with total thyroidectomy was ne-
cessary leading to removal of all four parathyroid glands.
Severe chronic postsurgical hypoparathyroidism devel-
oped rapidly. Despite optimal medical treatment with
high doses of oral calcium (3 g/day), cholecalciferol
(7000 IU/day) and calcitriol (2.0–3.75 μg/day) her cal-
cium level remained low (6.25 mg/dl; normal 8.6–
10.6 mg/dl) causing intolerable clinical hypocalcemic
symptoms including tetany and paresthesias. Moreover,
the patient frequently required hospitalization for i.v. cal-
cium administration. Five years after thyroid surgery add-
itional hormonal replacement therapy with parathyroid
hormone PTH (1–84) was started (subcutaneous injec-
tion: 100 μg/day). However, the patient’s symptoms im-
proved transiently for only three months. Altogether the
quality of life was considered very low. Thus, allotrans-
plantation of parathyroid glands for (definitive) treatment
of persistent symptomatic and refractory hypocalcemia
seemed an attractive therapeutic option. Despite of the
potential risks associated with lifelong immunosuppressive
therapy it was the distinct will of the patient to undergo
the allotransplantation procedure. The patient’s 31-year
old healthy brother expressed interest to be evaluated as a
potential donor. He was ABO compatible to the recipient
with no history of any relevant diseases and considered a
suitable donor. Importantly, preoperative calcium and
PTH-levels were within the normal range (Table 1). By
using contrast-enhanced ultrasonography (CEUS) [12],
three parathyroid glands (one left superior, one left infer-
ior, one right inferior) could exactly be localized preopera-
tively (Fig. 1a). Importantly, the Hospital Living-Donation
Committee as well as the Hospital Ethics Committee ap-
proved the planned operative procedure. After removing
the two left parathyroid glands from the donor through an
unilateral horizontal anterior neck incision (length 2.5 cm;
Fig. 1b) and histological confirmation by frozen section
the parathyroid tissue was fragmented into approximately
20 small particles (Fig. 1c) and implanted in the recipient’s
left forearm brachioradialis muscle. Based on the the im-
munosuppressive therapy regimen for kidney transplant-
ation, immunosuppression was initiated during surgery
before implantation of parathyroid tissue by prednisolone
i.v. (500 mg) and a perioperative single dose of basiliximab
(20 mg). Additionally, oral application of tacrolimus was
started six hours after surgery. Tacrolimus trough levels
were maintained in the 10–12 ng/ml range. On day five
after surgery, the patient received a second dose of basilix-
imab i.v. (20 mg). Prednisolone was reduced in a stepwise
fashion to a maintenance dose of 2.5 mg per day after six
months. Hormonal replacement therapy with PTH (1–84)
was stopped after transplantation. Neither the donor nor
the recipient experienced any surgical complications. The
donor was discharged from our hospital on the second
postoperative day and routine checks of calcium and
PTH-levels showed normal values after surgery (Table 1).
In the postoperative course of the recipient increasing
PTH levels were detectable and thereafter remained
within the normal range with a serum total PTH of 21 pg/
ml (normal range: 15–65 pg/ml) nearly three years after
transplantation (Table 2). Postoperative Casanova-Tests
Table 1 Serum calcium levels of the donor
Months after transplant
Preoperative Postoperative 3 6 12
Calcium [mg/dl] 9.2 8.8 9.2 8.4 8.8
No calcium or vitamin D supplementation; PTH within the normal range
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(venous blood samples for PTH measurement after infla-
tion of an armlet on the graft-bearing arm) clearly verified
the graft-bearing forearm as the source of increasing en-
dogenous PTH levels after transplantation. Moreover,
CEUS ten days posttransplant revealed vascularization of
the allograft (Fig. 1d). The calcium levels of the recipient
also returned into the normal range after parathyroid allo-
transplantation (Table 2). Consequently the former re-
placement therapy (calcium and vitamin D) could be
discontinued stepwise completely and was stopped on day
16 after the transplantation. Six months posttransplant an-
other Casanova-Test verified the functioning graft (PTH-
level before and after compression of the graft-bearing
forearm: 41 pg/ml and 5.9 pg/ml respectively). The patient
remained free of hypocalcemic symptoms to the present
day after a follow-up of 35 months so far.
Discussion
Surgery for thyroid or parathyroid disease is the leading
cause of hypoparathyroidism due to damage or (acciden-
tal) removal of parathyroid glands [2, 3, 13, 14]. In most
cases resulting hypocalcemia and corresponding hypo-
calcemic symptoms can easily be controlled by oral cal-
cium and vitamin D supplementation. However, in less
frequent cases (0,4 – 33 %) the usually transitory post-
surgical hypoparathyroidism persists for more than six
months causing serious metabolic disorders with long-
term risks of multiorgan calcinosis and renal failure [3].
Moreover, acute fall in serum calcium levels can even
cause life-threatenig symptoms. Affected patients may
frequently require i.v. calcium administration in addition
to high doses of oral calcium and vitamin D supple-
ments. Intractable hypocalcemic symptoms and repeated
hospitalizations significantly reduce the quality of life in
these patients [5]. Recently, novel synthetic PTH re-
placement therapies became available as a promising
treatment option for patients who do not respond well
to calcium and vitamin D supplementation alone. PTH
(1–84) (Natpara; whole molecule) and PTH (1–34) (For-
teo; active amino terminal portion) are injectable formu-
lations (subcutaneous injection) [6, 7]. However, animal
studies in rats showed that prolonged treatment with
PTH (1–84) and PTH (1–34) is associated with the de-
velopment of bone tumors (osteosarcoma) [15]. Al-
though to date this response has not been observed in
humans long-term therapy may be limited [16, 17].
Moreover, PTH (1–34) was approved by the Food and
Drug Administration (FDA) only for therapy of osteo-
porosis. Therefore, treatment for hypoparathyroidism re-
quires off label use. High monthly costs and an adequate
patient compliance (inconvenient daily injections) are
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Fig. 1 Living-donor allotransplantation of parathyroid glands. a Donor: preoperative localization of the parathyroid glands by CEUS b Donor:
retrieval of the parathyroid allograft c Parathyroid glands were cut into approximately 20 tissue particles of 1–2 mm size d Recipient: postsurgical
examination of the vascularization of transplanted parathyroid tissue by CEUS 10 days posttransplant
Table 2 PTH values and serum calcium levels posttransplant
(recipient)
Months after transplant
2 3 8 10 19 27 30 35
PTH [pg/ml] 22 21 24 35 17 18 17.5 21
Calcium [mg/dl] 9.6 9.6 9.2 9.6 8.4 9.2 9.6 9.2
Normal range: PTH: 15–65 pg/ml; serum calcium: 8.6–10.6 mg/dl
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further aspects that have to be taken into account before
starting a hormonal replacement therapy with either
PTH (1–84) or PTH (1–34) [18].
The most physiological and potentially definitive ther-
apy for persistent hypoparathyroidism would be a restor-
ation of parathyroid tissue in order to re-establish calcium
homeostasis. In this context parathyroid tissue allotrans-
plantation from deceased or living donors has been per-
formed sporadically over the past decades [8–11, 18].
Importantly, to avoid rejection of the graft lifelong im-
munosuppressive therapy of the recipient is necessary and
therefore adverse effects of immunosuppression (e.g. im-
paired kidney function, opportunist infections, cancer)
have to be carefully considered. However, searching the
literature several authors reported on alternative experi-
mental strategies to restore parathyroid tissue without the
need for immunosuppressive therapy, e.g. by using cul-
tured cells [8, 19], cryopreserved tissue [20, 21] or mag-
netic microspheres depletion of major histocompatibility
complex (MHC) of cells from parathyroid adenoma [8].
Microencapsulation of parathyroid tissue constitutes an-
other innovative concept aiming to exclude parathyroid
cells from a host-versus-graft reaction. While the trans-
plants are isolated from the immune system nutrients and
hormones may pass the semipermeable membrane of the
microcapsule. Initial results were encouraging showing
normal PTH levels from the third week after transplant-
ation [22] or graft survival up to 8 months [23]. However,
Bohrer et al. recently could demonstrate that the promis-
ing results of microencapsulation of allogeneic parathyroid
tissue are not due to the protection of the graft from the
immune system, but rather derive from delaying
immunization of the host [24]. Therefore, long-term ef-
fectiveness of this method may be limited.
The first successful parathyroid gland allotransplanta-
tion was published in 1973 by Growth et al. in a recipi-
ent who developed severe hypocalcemia after kidney
transplantation [10]. The donor was a patient with para-
thyroid hyperplasia. As the recipient was already under
immunosuppression and the donor needed surgical exci-
sion of parathyroid adenoma living donor allotransplan-
tation seemed an attractive and justified therapy. The
parathyroid graft survived 21 months. Since then several
authors have described this procedure achieving various
results concerning graft function [9, 25, 26]. Interest-
ingly, Alfrey et al. published a case of a renal transplant
patient with normocalcemia even 13 years after add-
itional successful parathyroid allotransplantation [27].
The first report of a healthy patient who donated two
parathyroid glands was published in 1975 by Wells et al.
[28]. The recipient was a renal failure patient requiring
total parathyroidectomy after kidney transplantation
resulting in hypoparathyroidism. The father of the pa-
tient who previously had been his renal transplant donor
additionally donated two healthy parathyroid glands
resulting in successful treatment of hypocalcemia and
associated symptoms of the recipient. The parathyroid
grafts showed a good function for more than one year.
Another similar report of a healthy patient donating one
parathyroid gland to a family member who previously
had undergone kidney transplantation shows a good func-
tionig graft two years after parathyroid allotransplantation
(normal PTH levels, oral calcium supplementation 1 g/
day) [29]. Only recently, Garcia-Roca published the first
successful case of simultaneous living donor kidney and
pararthyroid allotransplantation (healthy family member
donated kidney and one parathyroid gland) [30]. Nine
months after transplantation the recipient remains asymp-
tomatic with normal renal function and PTH levels (oral
calcium supplementation 2 g/day). The authors conclude
that parathyroid allograft transplantation can be justified
in recipients who receive immunosuppressive therapy for
another organ. However, for successful and potentially de-
finitive treatment of debilitating hypocalcemia that is
otherwise not controllable parathyroid gland allotrans-
plantion might as well be a reasonable option for patients
without immunosuppression because of previous trans-
plantation of another organ. In this context Hermosillo-
Sandoval et al. recently performed five parathyroid
allografts in patients with iatrogenic hypoparathyroidism
[31]. The living donors were patients with primary or sec-
ondary hyperparathyroidism requiring surgical excision.
Four of the grafts are functioning two years after allotrans-
plantation but calcium supplementation at a lower dose
than before the procedure is necessary. No adverse effects
of immunosuppression have been observed. In our case
study the recipient also suffered from iatrogenic (postsur-
gical) hypoparathyroidism. The patient was otherwise
healthy not receiving immunosuppressive therapy due to
previous transplantation of another organ. Nevertheless
parathyroid allotransplantation seemed a very attractive
therapeutic option in light of the unsuccessful medical
treatment including hormonal replacement therapy. To
date the graft shows excellent function without the need
for additional calcium supplementation. Furthermore, so
far no adverse effects of the immunosuppressive drugs oc-
curred and the patient significantly gained in quality of
life. Therefore, in our opinion parathyroid gland allotrans-
plantation can be justified also in nontransplant recipients.
However, prevention or early detection and treatment of
potential adverse effects of immunosuppression is the only
acceptable posttransplant strategy. An adequate patient
compliance and close long-term follow-up have to be
guaranteed. Moreover, as the procedure is elective and is-
chemia time is the shortest living donation seems most
advantageous. Against this background willing healthy
individuals (not requiring surgery for parathyroid disease)
might also be considered as donors. Although identification
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and removal of parathyroid tissue from a normocalcemic
healthy donor may be challenging due to small size of the
parathyroid glands, it is generally considered as a safe
procedure. Importantly, in the light of improved preopera-
tive localization of parathyroid glands by innovative diag-
nostic tools (Technetium-sestamibi scintigraphy, contrast-
enhanced ultrasonography) focused minimally invasive
organ retrieval causing only minimal trauma and excellent
cosmetic results has become standard.
Conclusion
Parathyroid gland allotransplantation is a valuable and
potentially definitive therapeutic option for patients with
intractable persistent hypoparathyroidism. Provided that
the well informed patient is willing to undergo trans-
plantation despite of potential adverse effects of im-
munosuppressive therapy parathyroid allotransplantation
can even be justified in nontransplant recipients. Living
donation from healthy donors is a safe procedure that
can be performed in minimally invasive technique.
Abbreviations
CEUS, contrast-enhanced ultrasonography; FDA, food and drug administration;
i.v., intravenous; MHC, Major histocompatibility complex; PTH, parathyroid
hormone.
Acknowledgement
The authors thank Prof. Dr. Henning Dralle (Department of Surgery, University
Hospital Halle (Saale), Germany) for excellent technical advice and essential
contribution to this study.
Funding
None.
Availability of data and materials
The datasets supporting the conclusions of this article are included within
the article.
Authors’ contributions
AA is the first author of the manuscript, proposed the technique, performed
the surgical procedure and treated the patient after surgery. MNS, CM, and
HJS treated the patient after surgery, substantially contributed to the draft of
the manuscript and revised the manuscript. TK and CG revised the manuscript,
treated the patient after surgery and collected data during the follow-up period.
FE performed pathohistological examination and revised the manuscript. EMJ
performed contrast-enhanced ultrasonography and revised the manuscript. AS
proposed the technique, treated the patient after surgery and revised the




The authors declare that they have no competing interests.
Consent for publication
Written informed consent was obtained from the patients for publication of
this Case report and any accompanying images. A copy of the written
consent is available for review by the Editor-in-Chief of this journal.
Ethics approval and consent to participate
Living-donor parathyroid allotransplantation was approved by the University
Hospital Regensburg Ethics Committee and the Universtiy Hospital Regensburg
Living-Donation Committee. Consent to participate was obtained from the
living-donor and the recipient.
Author details
1Department of Surgery, University Hospital Regensburg, Franz-Josef-Strauss-Allee
11, D-93053 Regensburg, Germany. 2Department of Internal Medicine I,
University Hospital Regensburg, D-93053 Regensburg, Germany. 3Medical Clinic
and Policlinic III, University Hospital Giessen, D-35392 Giessen, Germany.
4Department of Pathology, University Hospital Regensburg, D-93053 Regensburg,
Germany. 5Department of Radiology, University Hospital Regensburg, D-93053
Regensburg, Germany.
Received: 15 February 2016 Accepted: 22 July 2016
References
1. Shoback D. Clinical practice. Hypoparathyroidism. N Engl J Med. 2008;359:
391–403.
2. Testini M, Gurrado A, Lissidini G, Nacchiero M. Hypoparathyroidism after
total thyroidectomy. Minerva Chir. 2007;62(5):409–15.
3. Thomusch O, Machens A, Sekulla C, Ukkat J, Brauckhoff M, Dralle H. The
impact of surgical technique on postoperative hypoparathyroidism in
bilateral thyroid surgery: a multivariate analysis of 5846 consecutive patients.
Surgery. 2003;133(2):180–5.
4. Zarnegar R, Brunaud L, Clark OH. Prevention, evaluation, and management
of complications following thyroidectomy for thyroid carcinoma. Endocrinol
Metab Clin North Am. 2003;32(2):483–502.
5. De Sanctis V, Soliman A, Fiscina B. Hypoparathyroidism: from diagnosis to
treatment. Curr Opin Endocrinol Diabetes Obes. 2012;19(6):435–42.
6. Winer KK, Ko CW, Reynolds JC, Dowdy K, Keil M, Peterson D. Long-term
treatment of hypoparathyroidism: a randomized controlled study
comparing parathyroid hormone-(1–34) versus calcitriol and calcium. J Clin
Endocrinol Metab. 2003;88(9):4214–20.
7. Sikjaer T, Amstrup AK, Rolighed L, Kjaer SG, Mosekilde L, Rejnmark L. PTH
(1–84) replacement therapy in hypoparathyroidism: a randomized
controlled trial on pharmacokinetic and dynamic effects following 6 months
of treatment. J Bone Miner Res. 2013;28(10):2232–43.
8. Decker GA, Stark JH, Botha JR, Margolius LP, Decker G. Allotransplantation of
parathyroid cells. Lancet. 1995;14:124.
9. Torregrosa NM, Rodriguez JM, Llorente S, Balsalobre MD, Rios A, Jimeno L,
et al. Definitive treatment for persistent hypoparathyroidism in a kidney
transplant patient: parathyroid allotransplantation. Thyroid. 2005;15(11):
1299–302.
10. Groth CG, Hammond WS, Iwatsuki S, Popovitzer M, Cascardo S, Halgrimson
CG, et al. Survival of a homologous parathyroid implant in an
immunosuppressed patient. Lancet. 1973;19:1082–5.
11. Chapelle T, Meuris K, Roeyen G, De Greef K, Van Beeumen G, Bosmans JL,
et al. Simultaneous kidney-parathyroid allotransplantation from a single
donor after 20 years of tetany: a case report. Transplant Proc. 2009;41(2):
599–600.
12. Agha A, Hornung M, Stroszczynski C, Schlitt HJ, Jung EM. Highly efficient
localization of pathological glands in primary hyperparathyroidism using
contrast-enhanced ultrasonography (CEUS) in comparison with
conventional ultrasonography. J Clin Endocrinol Metab. 2013;98(5):2019–25.
13. Page C, Strunski V. Parathyroid risk in total thyroidectomy for bilateral,
benign, multinodular goitre: report of 351 surgical cases. J Laryngol Otol.
2007;121(3):237–41.
14. Asari R, Passler C, Kaczirek K, Scheuba C, Niederle B. Hypoparathyroidism
after total thyroidectomy: a prospective study. Arch Surg. 2008;143(2):132–7.
15. Vahle JL, Sato M, Long GG, Young JK, Francis PC, Engelhardt JA, et al.
Skeletal changes in rats given daily subcutaneous injections of recombinant
human parathyroid hormone (1–34) for 2 years and relevance to human
safety. Toxicol Pathol. 2002;30(3):312–21.
16. Andrews EB, Gilsenan AW, Midkiff K, Sherrill B, Wu Y, Mann BH, et al. The US
postmarketing surveillance study of adult osteosarcoma and teriparatide:
Study design and findings from the first 7 years. J Bone and Mineral Res.
2012;27(12):2429–37.
17. Capriani C, Irani D, Bilezikian JP. Safety of osteoanabolic therapy: a decade
of experience. J Bone and Mineral Res. 2012;27(12):2419–28.
18. Brown WH. Parathyroid implantation in the treatment of tetania
parathyreopriva. Ann Surg. 1911;53:305–17.
19. Stone HB, Owings JC, Grey GO. Transplantation of living grafts of thyroid
and parathyroid glands. Ann Surg. 1934;100:613–28.
Agha et al. BMC Surgery  (2016) 16:51 Page 5 of 6
20. Hasse C, Klöck G, Schlosser A, Zimmermann U, Rothmund M. Parathyroid
allotransplantation without immunosuppression. Lancet. 1997;350:1296–7.
21. Flechner SM, Berber E, Askar M, Stephany B, Agarwal A, Milas M.
Allotransplantation of cryopreserved parathyroid tissue for severe
hypocalcemia in a renal transplant recipient. Am J Transplant. 2010;10:2061–5.
22. Hasse C, Zielke A, Klöck G, Schlosser A, Zimmermann U, Rothmund M.
Isotransplantation of microencapsulated parathyroid tissue in rats. Exp Clin
Endocrinol Diabetes. 1997;105:53–6.
23. Cabane P, Gac P, Amat J, Pineda P, Rossi R, Caviedes R, et al. Allotransplant
of microencapsulated parathyroid tissue in severe postsurgical
hypoparathyroidism: a case report. Transplant Proc. 2009;41(9):3879–83.
24. Bohrer T, Stelter K, Stelter IS, Dietrich C, Sitter H, Hasse C.
Microencapsulation of allogeneic parathyroid tissue succeeds by delaying
immunization of the host, not by protecting the graft against the host’s
activated immune system. Transplantationsmedizin. 2008;18:36–42.
25. Duarte B, Mozes MF, John E, Aronson E, Pollak R, Jonasson O. Parathyroid
allotransplantation in the treatment of complicated idiopathic primary
hypoparathyroidism. Surgery. 1985;98:1072–6.
26. Belda Gonzalez I, del Moral JM, Perez NM, Soto JB, Orihuela JA. Parathyroid
allotransplantation as permanent treatment in a renal transplant patient. Cir
Esp. 2012;90:202–3.
27. Alfrey EJ, Perloff LJ, Asplund MW, Dafoe DC, Grossman RA, Bromberg JS, et
al. Normocalcemia thirteen years after successful parathyroid allografting in
a recipient of a renal transplant. Surgery. 1992;111:234–6.
28. Wells SA, Gunnells JC, Shelburne JD, Schneider AB, Sherwood LM.
Transplantation of the thyroid glands in man: clinical indications and results.
Surgery. 1975;78(1):34–4.
29. Giulianotti PC. D’Amico G, Tzvetanov I, Benedetti E. Living donor
parathyroid allotransplantation with robotic transaxillary procurement in a
kidney transplant recipient. Transpl Int. 2014;27:43–5.
30. Garcia-Roca R, Garcia-Aroz S, Tzvetanov IG, Giulianotti PC, Campara M,
Oberholzer J, et al. Simultaneous living donor kidney and parathyroid
allotransplantation: first case report and review of literature. Transplantation.
2016; [Epub ahead of print]
31. Hermosillo-Sandoval JM, Leonher-Ruezga KL, Jiménez-Gómez JA, Fuentes-
Orozco C, González-Ojeda A, Ramírez-González LR. Allogeneic parathyroid:
2-year follow-up. Cir Cir. 2015;83(3):188–92.
•  We accept pre-submission inquiries 
•  Our selector tool helps you to find the most relevant journal
•  We provide round the clock customer support 
•  Convenient online submission
•  Thorough peer review
•  Inclusion in PubMed and all major indexing services 
•  Maximum visibility for your research
Submit your manuscript at
www.biomedcentral.com/submit
Submit your next manuscript to BioMed Central 
and we will help you at every step:
Agha et al. BMC Surgery  (2016) 16:51 Page 6 of 6
